Evidence map›Paper›PMID 41004391›Full record

ArticleNeuroendocrinology2026

Multicenter Retrospective Study of Efficacy of Systemic Therapy in Patients with Neuroendocrine Tumor Grade 3 (JOSC-2001).

Hiroyuki Okuyama, Taro Shibuki, Naohiro Okano, Takuro Mizukami, Hiroaki Yanagimoto, Mao Okada, Emiri Kita, Noritoshi Kobayashi, Satoshi Kobayashi, Takaaki Furukawa and 18 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Hiroyuki OkuyamaDepartment of Medical Oncology, Kagawa University Hospital, Miki, Japan, okuyama.hiroyuki@kagawa-u.ac.jp.
Taro ShibukiDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Naohiro OkanoDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Takuro MizukamiDepartment of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
Hiroaki YanagimotoDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Mao OkadaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Emiri KitaDepartment of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
Noritoshi KobayashiDepartment of Oncology, Yokohama City University School of Medicine, Yokohama, Japan.
Satoshi KobayashiDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Takaaki FurukawaDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Hiroyuki AsamaDepartment of Gastroenterology, School of Medicine, Fukushima Medical University, Fukushima, Japan.
Hidetaka TsumuraDepartment of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan.
Ken KamataDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Kumiko UmemotoDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.
Yasuo HamamotoKeio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
Yuko SuzukiDepartment of Gastroenterology, Saitama Cancer Center, Saitama, Japan.
Shigeru HoriguchiDepartment of Gastroenterology and Hepatology, Okayama University Hospital, Okayama, Japan.
Atsushi NaganumaDepartment of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Akinori AsagiDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Kunihiro TsujiDepartment of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Ryoji TakadaDepartment of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Motohiro KojimaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
Hiroshi ImaokaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Takeshi TerashimaDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Masato OzakaDepartment of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Masafumi IkedaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroendocrine tumor G3 (NET G3) is a new category introduced in the WHO 2017 classification. Accordingly, evidence regarding chemotherapy for NET G3 is limited. A multicenter, retrospective analysis was performed to evaluate the outcomes of systemic therapy for NET G3 and to identify the optimal regimens.

methodsPatient demographic and treatment outcome data were retrospectively collected for 73 patients with pathologically diagnosed NET G3 who started chemotherapy at participating institutions between January 2011 and December 2019, excluding those who were ineligible by central pathological review. The chemotherapy regimens used and their efficacies were evaluated.

resultsOf the 73 patients, 47 had pancreatic NETs, 10 had gastrointestinal NETs, and 16 had NETs at other sites. Central pathological review was performed for 44 patients, with a concordance rate of 95%. Initial treatment regimens included NET-based treatment (somatostatin analog, molecular-targeted agent, cytotoxic chemotherapy such as streptozocin and temozolomide) for 37 patients, neuroendocrine carcinoma (NEC)-based treatment (platinum-containing chemotherapy) for 32 patients, and other regimens for 2 patients. There were no significant differences in progression-free survival (PFS) or overall survival (OS) between patients receiving NET-based and NEC-based treatment or among the individual treatment regimens. However, the response rate (RR) was higher for NET-based cytotoxic chemotherapy (50%) compared with NEC-based treatment (16%), suggesting greater efficacy of NET-based cytotoxic chemotherapy.

conclusionsAlthough no significant difference in PFS or OS was found among the chemotherapy regimens for NET G3, RR was notably higher for NET-based cytotoxic chemotherapy than for NEC-based treatment.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsGastrointestinal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm GradingRetrospective StudiesTreatment OutcomeAntineoplastic AgentsChemotherapyNeuroendocrine tumor G3Systemic therapy

Identifiers

PMID41004391
PMCPMC12795524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.